BusinessEsperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/AtorvastatinBy Nasdaq OMXMar 7, 2017, 1:30 PM UTC
BusinessEsperion Announces Oral Presentation on Genetic Validation of ATP Citrate Lyase Inhibition at the American College of Cardiology 66th Annual Scientific SessionBy Nasdaq OMXMar 6, 2017, 1:33 PM UTC
BusinessEsperion Announces Oral Presentation on Genetic Validation of ATP Citrate Lyase Inhibition at the American College of Cardiology 66th Annual Scientific SessionBy Nasdaq OMXMar 6, 2017, 1:33 PM UTC
BusinessEsperion Announces Oral Presentation on Genetic Validation of ATP Citrate Lyase Inhibition at the American College of Cardiology 66th Annual Scientific SessionBy Nasdaq OMXMar 6, 2017, 1:33 PM UTC
BusinessEsperion Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2016 Financial ResultsBy Nasdaq OMXFeb 22, 2017, 12:30 PM UTC
BusinessEsperion to Participate in Fireside Chat at RBC Capital Markets Global Healthcare ConferenceBy Nasdaq OMXFeb 15, 2017, 9:30 PM UTC
BusinessEsperion Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid in Patients with HypercholesterolemiaBy Nasdaq OMXJan 25, 2017, 1:05 PM UTC
BusinessEsperion Announces Initiation of Global Cardiovascular Outcomes Trial for Bempedoic AcidBy Nasdaq OMXJan 9, 2017, 1:05 PM UTC
